Stock Analiz

IGC Pharma, Inc. IGC

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.18Market cap $21M
Open the interactive analysis →

IGC Pharma, Inc. (IGC) is a healthcare company listed in the US with a market value of about $21M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$8M, a net margin of -643.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -21% a year, a 5-year average ROIC of -81%.

About IGC Pharma

IGC Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $8M in 2015 to $1M in 2025, a decline of about 16.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 288% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S16.3
P/B3.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-25.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-5.5%
Revenue growth (5 yrs, per year)-20.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1510.7%
ROIC (5-yr avg.)-81.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$1M$1M$911000$397000$898000$4M$5M$2M$580372$6M
Net income-$8M-$7M-$13M-$12M-$15M-$9M-$7M-$4M-$2M-$2M-$3M
Free cash flow-$5M-$5M-$5M-$7M-$8M-$12M-$13M-$3M-$2M-$2M-$279887
EPS (diluted)$-0.08$-0.09$-0.22$-0.22$-0.30$-0.21$-0.19$-0.00$-0.00$-0.07$-0.17
Net margin-643.7%-560.4%-966.5%-1263.0%-3782.4%-981.2%-179.6%-80.1%-81.4%-321.7%-44.1%
ROIC—-113.3%-127.8%-75.2%-63.0%-25.8%-25.3%-10.9%-22.2%-20.8%-16.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does IGC Pharma pay a dividend?

Not currently.

Is IGC Pharma a good stock to buy?

We do not give buy or sell advice. IGC Pharma scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.